 Todd Bull
Concepts (334)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hypertension, Pulmonary | 45 | 2024 | 1891 | 3.960 |
Why?
| | Scleroderma, Systemic | 6 | 2019 | 114 | 1.700 |
Why?
| | Pulmonary Embolism | 5 | 2022 | 212 | 1.280 |
Why?
| | Ventricular Dysfunction, Right | 7 | 2023 | 231 | 1.250 |
Why?
| | Vena Cava Filters | 2 | 2020 | 60 | 0.810 |
Why?
| | Thrombolytic Therapy | 3 | 2021 | 137 | 0.760 |
Why?
| | Epoprostenol | 5 | 2024 | 136 | 0.760 |
Why?
| | Adenocarcinoma, Mucinous | 1 | 2021 | 73 | 0.690 |
Why?
| | Airway Obstruction | 1 | 2021 | 154 | 0.660 |
Why?
| | Antihypertensive Agents | 3 | 2024 | 484 | 0.650 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 3 | 2024 | 998 | 0.630 |
Why?
| | Fibrinolytic Agents | 2 | 2021 | 262 | 0.610 |
Why?
| | Familial Primary Pulmonary Hypertension | 12 | 2023 | 198 | 0.600 |
Why?
| | Thrombosis | 4 | 2023 | 348 | 0.580 |
Why?
| | Oligonucleotide Array Sequence Analysis | 5 | 2010 | 754 | 0.570 |
Why?
| | Extracorporeal Membrane Oxygenation | 2 | 2020 | 285 | 0.570 |
Why?
| | Growth Differentiation Factor 15 | 3 | 2013 | 40 | 0.530 |
Why?
| | Vascular Resistance | 5 | 2021 | 369 | 0.520 |
Why?
| | Herpesviridae Infections | 3 | 2008 | 142 | 0.510 |
Why?
| | Exercise Test | 4 | 2024 | 608 | 0.510 |
Why?
| | Endovascular Procedures | 1 | 2020 | 301 | 0.500 |
Why?
| | Hypoxia | 6 | 2024 | 1081 | 0.500 |
Why?
| | Patient Outcome Assessment | 1 | 2017 | 126 | 0.490 |
Why?
| | Altitude Sickness | 1 | 2017 | 141 | 0.480 |
Why?
| | Pulmonary Artery | 10 | 2023 | 1075 | 0.450 |
Why?
| | Vasodilator Agents | 4 | 2023 | 325 | 0.440 |
Why?
| | Echocardiography | 2 | 2020 | 635 | 0.430 |
Why?
| | Humans | 69 | 2024 | 129527 | 0.430 |
Why?
| | Ventricular Function, Right | 5 | 2024 | 276 | 0.420 |
Why?
| | Pancreatic Neoplasms | 1 | 2021 | 875 | 0.420 |
Why?
| | Perioperative Care | 1 | 2014 | 165 | 0.390 |
Why?
| | Altitude | 1 | 2017 | 462 | 0.390 |
Why?
| | Anticoagulants | 5 | 2023 | 637 | 0.390 |
Why?
| | Endothelial Cells | 5 | 2011 | 739 | 0.380 |
Why?
| | Sulfones | 1 | 2012 | 108 | 0.370 |
Why?
| | Oxygen Consumption | 2 | 2024 | 663 | 0.350 |
Why?
| | Blood Cells | 1 | 2010 | 38 | 0.350 |
Why?
| | Venous Thromboembolism | 3 | 2021 | 287 | 0.330 |
Why?
| | Herpesvirus 8, Human | 3 | 2008 | 60 | 0.330 |
Why?
| | Hypertension, Portal | 2 | 2020 | 61 | 0.330 |
Why?
| | Piperazines | 1 | 2012 | 339 | 0.320 |
Why?
| | Blood Coagulation | 3 | 2021 | 239 | 0.320 |
Why?
| | Neovascularization, Pathologic | 1 | 2011 | 292 | 0.310 |
Why?
| | End Stage Liver Disease | 2 | 2020 | 79 | 0.310 |
Why?
| | Virus Diseases | 1 | 2011 | 210 | 0.300 |
Why?
| | Lung | 8 | 2022 | 3928 | 0.280 |
Why?
| | Walk Test | 2 | 2024 | 70 | 0.270 |
Why?
| | Acute Lung Injury | 1 | 2010 | 280 | 0.270 |
Why?
| | Time Factors | 2 | 2017 | 6530 | 0.270 |
Why?
| | Middle Aged | 20 | 2024 | 31087 | 0.260 |
Why?
| | Blood Vessels | 1 | 2008 | 184 | 0.260 |
Why?
| | Male | 28 | 2024 | 63586 | 0.250 |
Why?
| | Heart Ventricles | 5 | 2024 | 778 | 0.250 |
Why?
| | Mixed Connective Tissue Disease | 1 | 2005 | 10 | 0.240 |
Why?
| | Microarray Analysis | 1 | 2005 | 113 | 0.240 |
Why?
| | Respiratory Function Tests | 1 | 2007 | 581 | 0.240 |
Why?
| | Muscle, Smooth, Vascular | 3 | 2007 | 441 | 0.230 |
Why?
| | Female | 27 | 2024 | 68650 | 0.230 |
Why?
| | Cardiac Catheterization | 5 | 2023 | 519 | 0.230 |
Why?
| | Aromatase Inhibitors | 1 | 2024 | 51 | 0.230 |
Why?
| | Pulmonary Emphysema | 2 | 2007 | 275 | 0.220 |
Why?
| | Castleman Disease | 1 | 2003 | 13 | 0.210 |
Why?
| | Exercise | 4 | 2024 | 1931 | 0.200 |
Why?
| | Gene Expression Profiling | 2 | 2007 | 1684 | 0.200 |
Why?
| | Heparin | 2 | 2021 | 253 | 0.190 |
Why?
| | Biopsy | 1 | 2005 | 1087 | 0.190 |
Why?
| | Vascular Neoplasms | 1 | 2022 | 17 | 0.190 |
Why?
| | Cross-Over Studies | 1 | 2024 | 522 | 0.190 |
Why?
| | Endothelium, Vascular | 6 | 2007 | 895 | 0.190 |
Why?
| | Cholangiopancreatography, Magnetic Resonance | 1 | 2021 | 16 | 0.180 |
Why?
| | Embolectomy | 1 | 2020 | 13 | 0.170 |
Why?
| | Aromatase | 1 | 2020 | 31 | 0.170 |
Why?
| | Growth Differentiation Factor 2 | 1 | 2020 | 2 | 0.170 |
Why?
| | Forced Expiratory Volume | 1 | 2021 | 508 | 0.170 |
Why?
| | Aged | 12 | 2024 | 22063 | 0.170 |
Why?
| | Hepatopulmonary Syndrome | 1 | 2020 | 24 | 0.170 |
Why?
| | Pulmonary Circulation | 4 | 2023 | 428 | 0.170 |
Why?
| | Thrombectomy | 1 | 2020 | 58 | 0.170 |
Why?
| | Tuberculosis | 1 | 2003 | 273 | 0.160 |
Why?
| | Drug Resistance | 1 | 2020 | 163 | 0.160 |
Why?
| | Tissue Plasminogen Activator | 1 | 2021 | 222 | 0.160 |
Why?
| | Bone Morphogenetic Proteins | 1 | 2020 | 129 | 0.160 |
Why?
| | Risk Factors | 7 | 2018 | 9779 | 0.150 |
Why?
| | Vascular Stiffness | 1 | 2023 | 467 | 0.150 |
Why?
| | Sildenafil Citrate | 2 | 2023 | 58 | 0.150 |
Why?
| | Polymerase Chain Reaction | 3 | 2008 | 1031 | 0.150 |
Why?
| | Critical Illness | 2 | 2021 | 758 | 0.140 |
Why?
| | Respiratory Insufficiency | 1 | 2021 | 312 | 0.140 |
Why?
| | Estrogens | 1 | 2020 | 346 | 0.140 |
Why?
| | Pulmonary Wedge Pressure | 1 | 2018 | 66 | 0.140 |
Why?
| | Acute Disease | 1 | 2020 | 975 | 0.140 |
Why?
| | Betacoronavirus | 1 | 2020 | 252 | 0.140 |
Why?
| | Hemodynamics | 2 | 2014 | 1094 | 0.140 |
Why?
| | Thrombospondin 1 | 1 | 2017 | 26 | 0.140 |
Why?
| | Schistosoma | 1 | 2017 | 28 | 0.140 |
Why?
| | Purines | 2 | 2023 | 171 | 0.140 |
Why?
| | Transforming Growth Factor beta | 2 | 2017 | 462 | 0.130 |
Why?
| | Natriuretic Peptide, Brain | 2 | 2021 | 99 | 0.130 |
Why?
| | Risk Assessment | 3 | 2023 | 3255 | 0.130 |
Why?
| | Adult | 15 | 2024 | 35505 | 0.130 |
Why?
| | Echocardiography, Doppler, Color | 1 | 2016 | 40 | 0.130 |
Why?
| | Bone Marrow Cells | 1 | 2017 | 302 | 0.130 |
Why?
| | Pandemics | 2 | 2021 | 1500 | 0.130 |
Why?
| | Treatment Outcome | 8 | 2024 | 10232 | 0.120 |
Why?
| | Systole | 1 | 2016 | 190 | 0.120 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 342 | 0.120 |
Why?
| | Coronavirus Infections | 1 | 2020 | 336 | 0.120 |
Why?
| | Clinical Trials as Topic | 2 | 2013 | 1001 | 0.120 |
Why?
| | Patient Care Team | 1 | 2020 | 600 | 0.120 |
Why?
| | Retrospective Studies | 8 | 2023 | 14532 | 0.120 |
Why?
| | Intensive Care Units | 1 | 2020 | 737 | 0.120 |
Why?
| | Cohort Studies | 3 | 2017 | 5423 | 0.120 |
Why?
| | Prognosis | 3 | 2013 | 3772 | 0.120 |
Why?
| | Health Surveys | 1 | 2017 | 493 | 0.110 |
Why?
| | Myocardial Contraction | 1 | 2016 | 334 | 0.110 |
Why?
| | Fibrin Fibrinogen Degradation Products | 2 | 2011 | 82 | 0.110 |
Why?
| | ROC Curve | 1 | 2016 | 503 | 0.110 |
Why?
| | Heart Failure | 2 | 2020 | 2143 | 0.110 |
Why?
| | Blood Pressure | 2 | 2016 | 1735 | 0.110 |
Why?
| | Positive-Pressure Respiration | 1 | 2014 | 78 | 0.110 |
Why?
| | Heart-Assist Devices | 1 | 2020 | 538 | 0.110 |
Why?
| | Anesthetics | 1 | 2014 | 75 | 0.110 |
Why?
| | Precision Medicine | 1 | 2017 | 385 | 0.100 |
Why?
| | Lung Diseases, Interstitial | 2 | 2013 | 611 | 0.100 |
Why?
| | Respiratory System Agents | 1 | 2013 | 22 | 0.100 |
Why?
| | Drug Discovery | 1 | 2013 | 131 | 0.100 |
Why?
| | Leukocytes, Mononuclear | 2 | 2007 | 546 | 0.100 |
Why?
| | Follow-Up Studies | 3 | 2021 | 4891 | 0.100 |
Why?
| | Practice Guidelines as Topic | 1 | 2020 | 1510 | 0.100 |
Why?
| | Drug Storage | 1 | 2012 | 58 | 0.100 |
Why?
| | Phenotype | 3 | 2010 | 3058 | 0.100 |
Why?
| | Drug Stability | 1 | 2012 | 160 | 0.100 |
Why?
| | Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 1 | 2011 | 24 | 0.090 |
Why?
| | Drug Approval | 1 | 2012 | 86 | 0.090 |
Why?
| | Ventilation-Perfusion Ratio | 1 | 2011 | 10 | 0.090 |
Why?
| | Reproducibility of Results | 2 | 2010 | 3081 | 0.090 |
Why?
| | Heparin, Low-Molecular-Weight | 1 | 2011 | 29 | 0.090 |
Why?
| | Troponin | 1 | 2011 | 50 | 0.090 |
Why?
| | Europe | 1 | 2012 | 362 | 0.090 |
Why?
| | Blood Gas Analysis | 1 | 2011 | 73 | 0.090 |
Why?
| | Case-Control Studies | 4 | 2020 | 3383 | 0.090 |
Why?
| | Hyponatremia | 1 | 2011 | 39 | 0.090 |
Why?
| | Pregnancy Complications, Cardiovascular | 1 | 2011 | 78 | 0.090 |
Why?
| | Medical History Taking | 1 | 2011 | 117 | 0.090 |
Why?
| | Antithrombins | 1 | 2011 | 58 | 0.090 |
Why?
| | Ultrasonography | 2 | 2011 | 708 | 0.090 |
Why?
| | Magnetic Resonance Imaging | 4 | 2023 | 3392 | 0.090 |
Why?
| | Double-Blind Method | 3 | 2024 | 1873 | 0.090 |
Why?
| | Receptors, Interleukin-7 | 1 | 2010 | 27 | 0.090 |
Why?
| | Registries | 3 | 2022 | 1902 | 0.080 |
Why?
| | Predictive Value of Tests | 4 | 2023 | 1950 | 0.080 |
Why?
| | Mutation, Missense | 1 | 2011 | 315 | 0.080 |
Why?
| | Demography | 1 | 2010 | 279 | 0.080 |
Why?
| | Drug Delivery Systems | 1 | 2012 | 337 | 0.080 |
Why?
| | Aldosterone | 1 | 2009 | 43 | 0.080 |
Why?
| | Cluster Analysis | 1 | 2010 | 483 | 0.080 |
Why?
| | Lung Neoplasms | 1 | 2022 | 2342 | 0.080 |
Why?
| | Vasopressins | 1 | 2009 | 64 | 0.080 |
Why?
| | Prospective Studies | 4 | 2022 | 7150 | 0.070 |
Why?
| | Caspase 7 | 1 | 2008 | 22 | 0.070 |
Why?
| | Vasoconstrictor Agents | 1 | 2009 | 127 | 0.070 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 952 | 0.070 |
Why?
| | In Situ Nick-End Labeling | 1 | 2008 | 123 | 0.070 |
Why?
| | Bone Morphogenetic Protein 4 | 1 | 2008 | 38 | 0.070 |
Why?
| | Electrocardiography | 1 | 2011 | 612 | 0.070 |
Why?
| | Culture Media, Conditioned | 1 | 2008 | 109 | 0.070 |
Why?
| | Intramolecular Oxidoreductases | 2 | 2005 | 68 | 0.070 |
Why?
| | United States | 4 | 2022 | 13865 | 0.070 |
Why?
| | Research Design | 1 | 2013 | 1043 | 0.070 |
Why?
| | Animals | 10 | 2017 | 35334 | 0.070 |
Why?
| | Fluorescent Antibody Technique | 1 | 2008 | 376 | 0.070 |
Why?
| | Cytochrome P-450 Enzyme System | 2 | 2005 | 151 | 0.070 |
Why?
| | Caspase 3 | 1 | 2008 | 244 | 0.070 |
Why?
| | Acrolein | 1 | 2007 | 23 | 0.070 |
Why?
| | Survival Analysis | 1 | 2010 | 1270 | 0.070 |
Why?
| | Colorado | 1 | 2017 | 4403 | 0.070 |
Why?
| | Flow Cytometry | 1 | 2010 | 1158 | 0.070 |
Why?
| | Multivariate Analysis | 1 | 2010 | 1491 | 0.060 |
Why?
| | Hypertrophy, Right Ventricular | 1 | 2007 | 144 | 0.060 |
Why?
| | Quality of Life | 3 | 2022 | 2694 | 0.060 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2008 | 836 | 0.060 |
Why?
| | Endothelin A Receptor Antagonists | 1 | 2005 | 24 | 0.060 |
Why?
| | Pleural Diseases | 1 | 2005 | 18 | 0.060 |
Why?
| | Comorbidity | 1 | 2010 | 1548 | 0.060 |
Why?
| | Endothelial Growth Factors | 2 | 2002 | 63 | 0.060 |
Why?
| | Phosphodiesterase Inhibitors | 1 | 2005 | 89 | 0.060 |
Why?
| | Lymphokines | 2 | 2002 | 127 | 0.060 |
Why?
| | Cells, Cultured | 2 | 2011 | 4087 | 0.060 |
Why?
| | Interleukin-6 | 1 | 2008 | 724 | 0.060 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2010 | 1058 | 0.060 |
Why?
| | Carrier Proteins | 1 | 2008 | 740 | 0.050 |
Why?
| | Cattle | 2 | 2017 | 959 | 0.050 |
Why?
| | Apoptosis | 3 | 2008 | 2488 | 0.050 |
Why?
| | Algorithms | 1 | 2011 | 1614 | 0.050 |
Why?
| | Vasodilation | 3 | 2010 | 476 | 0.050 |
Why?
| | Nitriles | 1 | 2024 | 169 | 0.050 |
Why?
| | Blood Circulation | 1 | 2003 | 41 | 0.050 |
Why?
| | CD36 Antigens | 1 | 2003 | 36 | 0.050 |
Why?
| | E-Selectin | 1 | 2003 | 55 | 0.050 |
Why?
| | Forecasting | 1 | 2005 | 360 | 0.050 |
Why?
| | Adolescent | 4 | 2021 | 20409 | 0.050 |
Why?
| | Veins | 1 | 2003 | 60 | 0.050 |
Why?
| | Biomarkers | 4 | 2013 | 3968 | 0.050 |
Why?
| | Blood | 1 | 2003 | 105 | 0.050 |
Why?
| | Neoplasm Metastasis | 1 | 2005 | 609 | 0.050 |
Why?
| | Blood Donors | 1 | 2004 | 97 | 0.050 |
Why?
| | Postmenopause | 1 | 2024 | 349 | 0.050 |
Why?
| | Pulmonary Alveoli | 1 | 2005 | 403 | 0.050 |
Why?
| | Administration, Inhalation | 1 | 2024 | 673 | 0.050 |
Why?
| | Drug Therapy, Combination | 1 | 2005 | 1037 | 0.050 |
Why?
| | Immunophenotyping | 1 | 2003 | 310 | 0.050 |
Why?
| | Drainage | 1 | 2003 | 164 | 0.050 |
Why?
| | Receptors, Growth Factor | 1 | 2002 | 55 | 0.050 |
Why?
| | Disease Models, Animal | 2 | 2016 | 4073 | 0.050 |
Why?
| | Vascular Diseases | 1 | 2005 | 240 | 0.050 |
Why?
| | Partial Thromboplastin Time | 1 | 2021 | 52 | 0.050 |
Why?
| | Histone Deacetylase Inhibitors | 1 | 2023 | 208 | 0.040 |
Why?
| | Promoter Regions, Genetic | 1 | 2005 | 1211 | 0.040 |
Why?
| | Vascular Remodeling | 1 | 2023 | 189 | 0.040 |
Why?
| | Cytochrome P-450 CYP1B1 | 1 | 2020 | 5 | 0.040 |
Why?
| | Rivaroxaban | 1 | 2023 | 252 | 0.040 |
Why?
| | Brachial Artery | 2 | 1999 | 192 | 0.040 |
Why?
| | Lymph Nodes | 1 | 2003 | 471 | 0.040 |
Why?
| | Catheters | 1 | 2021 | 70 | 0.040 |
Why?
| | Cross-Sectional Studies | 2 | 2022 | 5078 | 0.040 |
Why?
| | Proteomics | 2 | 2022 | 1053 | 0.040 |
Why?
| | Liver Function Tests | 1 | 2020 | 112 | 0.040 |
Why?
| | United Kingdom | 1 | 2021 | 257 | 0.040 |
Why?
| | Blood Coagulation Tests | 1 | 2020 | 60 | 0.040 |
Why?
| | Receptor Protein-Tyrosine Kinases | 1 | 2002 | 231 | 0.040 |
Why?
| | Mass Screening | 1 | 2007 | 1186 | 0.040 |
Why?
| | Outpatients | 1 | 2023 | 375 | 0.040 |
Why?
| | Estrogen Receptor alpha | 1 | 2020 | 129 | 0.040 |
Why?
| | Smoking | 1 | 2007 | 1501 | 0.040 |
Why?
| | Immunohistochemistry | 1 | 2003 | 1684 | 0.040 |
Why?
| | Social Determinants of Health | 1 | 2022 | 226 | 0.040 |
Why?
| | Drug Monitoring | 1 | 2020 | 214 | 0.040 |
Why?
| | Proportional Hazards Models | 1 | 2022 | 1196 | 0.040 |
Why?
| | Gene Expression Regulation | 1 | 2008 | 2544 | 0.040 |
Why?
| | Hemorrhage | 1 | 2023 | 680 | 0.040 |
Why?
| | Enalapril | 1 | 1998 | 16 | 0.040 |
Why?
| | Survival Rate | 1 | 2022 | 1870 | 0.030 |
Why?
| | Antigens, Ly | 1 | 2017 | 44 | 0.030 |
Why?
| | Host-Pathogen Interactions | 1 | 2020 | 355 | 0.030 |
Why?
| | National Heart, Lung, and Blood Institute (U.S.) | 1 | 2017 | 103 | 0.030 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 1 | 1998 | 197 | 0.030 |
Why?
| | Bone Morphogenetic Protein Receptors, Type II | 2 | 2010 | 51 | 0.030 |
Why?
| | Peptide Fragments | 1 | 2021 | 695 | 0.030 |
Why?
| | Education | 1 | 2017 | 103 | 0.030 |
Why?
| | Patient Acceptance of Health Care | 1 | 2022 | 761 | 0.030 |
Why?
| | Th2 Cells | 1 | 2017 | 171 | 0.030 |
Why?
| | Signal Transduction | 2 | 2020 | 4916 | 0.030 |
Why?
| | Cell Proliferation | 1 | 2023 | 2367 | 0.030 |
Why?
| | Basic Helix-Loop-Helix Transcription Factors | 1 | 2017 | 235 | 0.030 |
Why?
| | Monocytes | 1 | 2017 | 554 | 0.030 |
Why?
| | Stress, Mechanical | 1 | 2016 | 461 | 0.030 |
Why?
| | Animals, Newborn | 1 | 2016 | 827 | 0.030 |
Why?
| | Catheterization, Swan-Ganz | 1 | 2013 | 8 | 0.030 |
Why?
| | Hospitalization | 1 | 2023 | 2076 | 0.030 |
Why?
| | Tomography, X-Ray Computed | 1 | 2003 | 2503 | 0.030 |
Why?
| | Biomechanical Phenomena | 1 | 2016 | 723 | 0.030 |
Why?
| | Mice | 2 | 2007 | 16973 | 0.030 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2020 | 2062 | 0.030 |
Why?
| | Perioperative Period | 1 | 2012 | 52 | 0.020 |
Why?
| | Liver Transplantation | 1 | 2020 | 833 | 0.020 |
Why?
| | Fluid Therapy | 1 | 2013 | 133 | 0.020 |
Why?
| | Sp1 Transcription Factor | 1 | 2011 | 24 | 0.020 |
Why?
| | International Cooperation | 1 | 2012 | 177 | 0.020 |
Why?
| | Cell Growth Processes | 1 | 2011 | 49 | 0.020 |
Why?
| | Vascular Endothelial Growth Factors | 2 | 2002 | 78 | 0.020 |
Why?
| | Radionuclide Imaging | 1 | 2011 | 115 | 0.020 |
Why?
| | Aged, 80 and over | 2 | 2018 | 7052 | 0.020 |
Why?
| | Conserved Sequence | 1 | 2011 | 227 | 0.020 |
Why?
| | Inflammation | 1 | 2022 | 2741 | 0.020 |
Why?
| | Nitric Oxide | 2 | 2010 | 897 | 0.020 |
Why?
| | Introns | 1 | 2011 | 249 | 0.020 |
Why?
| | Radiography, Thoracic | 1 | 2011 | 165 | 0.020 |
Why?
| | Physical Examination | 1 | 2012 | 233 | 0.020 |
Why?
| | Radiation Dosage | 1 | 2011 | 154 | 0.020 |
Why?
| | Lung Transplantation | 1 | 2013 | 290 | 0.020 |
Why?
| | RNA Splicing | 1 | 2011 | 259 | 0.020 |
Why?
| | Leg | 1 | 2011 | 222 | 0.020 |
Why?
| | Anesthesia | 1 | 2012 | 172 | 0.020 |
Why?
| | Myocytes, Smooth Muscle | 1 | 2011 | 257 | 0.020 |
Why?
| | RNA, Messenger | 1 | 2017 | 2697 | 0.020 |
Why?
| | Vascular Endothelial Growth Factor A | 2 | 2002 | 527 | 0.020 |
Why?
| | Spironolactone | 1 | 2009 | 30 | 0.020 |
Why?
| | Mineralocorticoid Receptor Antagonists | 1 | 2009 | 46 | 0.020 |
Why?
| | Contrast Media | 1 | 2011 | 393 | 0.020 |
Why?
| | Polymorphism, Genetic | 1 | 2011 | 636 | 0.020 |
Why?
| | Mutation | 3 | 2005 | 3702 | 0.020 |
Why?
| | Binding Sites | 1 | 2011 | 1250 | 0.020 |
Why?
| | Health Status Indicators | 1 | 2009 | 166 | 0.020 |
Why?
| | Endothelin-1 | 1 | 2010 | 178 | 0.020 |
Why?
| | Mice, Inbred C57BL | 1 | 2017 | 5468 | 0.020 |
Why?
| | Research | 1 | 2009 | 419 | 0.020 |
Why?
| | Protein Binding | 1 | 2011 | 2121 | 0.020 |
Why?
| | Young Adult | 1 | 2021 | 12438 | 0.010 |
Why?
| | Gene Expression | 1 | 2010 | 1461 | 0.010 |
Why?
| | Cell Culture Techniques | 1 | 2007 | 347 | 0.010 |
Why?
| | DNA-Binding Proteins | 1 | 2011 | 1438 | 0.010 |
Why?
| | Cell Count | 1 | 2005 | 318 | 0.010 |
Why?
| | Pilot Projects | 1 | 2009 | 1594 | 0.010 |
Why?
| | Transcription Factors | 1 | 2011 | 1642 | 0.010 |
Why?
| | Genes, Viral | 1 | 2003 | 82 | 0.010 |
Why?
| | Cyclins | 1 | 2003 | 88 | 0.010 |
Why?
| | Disease Progression | 1 | 2010 | 2628 | 0.010 |
Why?
| | Receptors, Vascular Endothelial Growth Factor | 1 | 2002 | 107 | 0.010 |
Why?
| | Hematopoietic Stem Cells | 1 | 2005 | 382 | 0.010 |
Why?
| | DNA, Viral | 1 | 2003 | 347 | 0.010 |
Why?
| | Mice, Transgenic | 1 | 2007 | 2135 | 0.010 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 1998 | 3622 | 0.010 |
Why?
| | Postoperative Complications | 1 | 2012 | 2475 | 0.010 |
Why?
| | Viral Proteins | 1 | 2003 | 327 | 0.010 |
Why?
| | Microsatellite Repeats | 1 | 2001 | 163 | 0.010 |
Why?
| | Sequence Analysis, DNA | 1 | 2003 | 776 | 0.010 |
Why?
| | Ovarian Neoplasms | 1 | 2005 | 482 | 0.010 |
Why?
| | Vasoconstriction | 1 | 2001 | 199 | 0.010 |
Why?
| | Surveys and Questionnaires | 1 | 2012 | 5429 | 0.010 |
Why?
| | Protein Isoforms | 1 | 2001 | 392 | 0.010 |
Why?
| | Ultrasonography, Doppler, Pulsed | 1 | 1999 | 7 | 0.010 |
Why?
| | Administration, Sublingual | 1 | 1999 | 10 | 0.010 |
Why?
| | Nitroglycerin | 1 | 1999 | 17 | 0.010 |
Why?
| | Pregnancy | 1 | 2011 | 6412 | 0.010 |
Why?
| | Lipoprotein(a) | 1 | 1999 | 66 | 0.010 |
Why?
| | Cholesterol, HDL | 1 | 1999 | 197 | 0.010 |
Why?
| | Video Recording | 1 | 1999 | 163 | 0.010 |
Why?
| | Fibrinogen | 1 | 1999 | 164 | 0.010 |
Why?
| | Arteriosclerosis | 1 | 1998 | 85 | 0.010 |
Why?
| | Blood Flow Velocity | 1 | 1999 | 406 | 0.010 |
Why?
| | Reference Values | 1 | 1999 | 795 | 0.010 |
Why?
| | Diabetic Angiopathies | 1 | 1998 | 256 | 0.010 |
Why?
| | Regression Analysis | 1 | 1998 | 994 | 0.010 |
Why?
| | Military Personnel | 1 | 1999 | 518 | 0.010 |
Why?
|
|
Bull's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|